Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

Inclusion Criteria:

* ≥ 18 years old
* Histologically or cytologically confirmed diagnosis of NSCLC
* Inoperable Stage IIIA, unresectable Stage IIIB or metastatic NSCLC patients who have received 1 prior platinum-based chemotherapy regimen
* Measurable disease per RECIST
* ECOG performance status score of 0 or 1
* Willing and able to provide written informed consent

Exclusion Criteria:

* Laboratory values of: ANC \< 1500/mm³, Platelet count \< 100,000/mm³, hemoglobin \< 10 g/dL, AST or ALT \> 2.5 x upper limit of normal (ULN), Alkaline phosphatase \> 5 x ULN, bilirubin \> 1.5 x ULN, serum creatinine \> 2.0 mg/dL (176 umol/dL), albumin \< 3.0 g/dL (30 g/L)
* Symptomatic or uncontrolled (untreated or treated and progressing) brain metastases
* Evidence of meningeal metastasis
* \> 1 prior cytotoxic regimen (not counting adjuvant or neo-adjuvant cytotoxic chemotherapy if completed \> 12 months prior to cytotoxic regimen, or prior MGd)
* Chemotherapy, radiation therapy, experimental therapy, immunotherapy, or systemic biologic anticancer therapy within 21 days before beginning study treatment
* Significant weight loss ≥ 10% of body weight within preceding 6 weeks
* Treatment for another cancer within 3 years before enrollment, except basal cell carcinoma of the skin or cervical cancer in situ
* Myocardial infarction within 6 months of enrollment or congestive heart failure rated New York Heart Association Class III or IV
* Uncontrolled hypertension (systolic blood pressure \> 160 mm Hg and diastolic blood pressure \> 110 mm Hg on maximal medical therapy)
* Known history of porphyria (testing not required at screening visit)
* Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency (testing not required at screening visit)
* History of hypersensitivity to taxanes or polysorbate 80
* Known history of HIV infection (testing not required at screening visit)
* Female who is pregnant or lactating (serum pregnancy test is required for all female patients of childbearing potential)
* Sexually active male or female of childbearing potential unwilling to use adequate contraceptive protection
* Physical or mental condition that makes patient unable to complete specified follow-up assessments